Brief: Vivos Therapeutics Provides Update On Revenue Recognition Review
22/11/2022 12:35
Nov 22 (Reuters) - Vivos Therapeutics Inc VVOS.O :
* VIVOS THERAPEUTICS PROVIDES UPDATE ON REVENUE RECOGNITION
REVIEW
* VIVOS THERAPEUTICS INC - DETAILED ANALYSIS FINDS MINIMAL
IMPACT
ON PRIOR FINANCIAL RESULTS; NO PREVIOUSLY REPORTED REVENUE TO BE
LOST
* VIVOS THERAPEUTICS INC - PREVIOUSLY REPORTED Q1 2022
REVENUE
EXPECTED TO INCREASE APPROXIMATELY $200,000
* VIVOS THERAPEUTICS INC - NO NEED TO RESTATE PRIOR YEAR
FINANCIAL
STATEMENTS
* VIVOS THERAPEUTICS INC - RESTATED Q1 2022 RESULTS TO BE
FILED
SHORTLY;SECOND AND Q3 2022 FINANCIAL RESULTS EXPECTED BY YEAR
END
Source text for Eikon: ID:nGNX7tw7S8
Further company coverage: VVOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth